版本:
中国

BRIEF-FDA approves two of Gilead's hepatitis C drugs for pediatric patients

April 7 Gilead Sciences Inc :

* U.S. FDA approves new indications for Harvoni and Sovaldi in pediatric patients 12 years and older with chronic hepatitis C infection

* Harvoni, Sovaldi each have boxed warning in their respective product labels

* Boxed warning for the two drugs relate to risk of hepatitis B virus reactivation in HCV/HBV co-infected patients Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐